|
JP2020189888A
|
|
Quinolone analog and form of salt thereof
|
|
WO2012054493A1
|
|
Deuterated serine-threonine protein kinase modulators
|
|
WO2011041785A1
|
|
Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors
|
|
WO2011035022A1
|
|
Tricyclic compounds and pharmaceutical uses thereof
|
|
AU2010295619A1
|
|
Novel tricyclic protein kinase modulators
|
|
MX2012002994A
|
|
Pharmaceutically useful heterocycle-substituted lactams.
|
|
AU2010286691A1
|
|
Condensed quinolines as protein kinase modulators
|
|
WO2010148351A1
|
|
Rhodanines and related heterocycles as kinase inhibitors
|
|
WO2010135571A1
|
|
Novel protein kinase modulators
|
|
AU2010249493A1
|
|
Pyrazolopyrimidines and related heterocycles as kinase inhibitors
|
|
SG175210A1
|
|
Method of treating disorders associated with protein kinase ck2 activity
|
|
CN102137866A
|
|
Oxindole compounds
|
|
MX2011007384A
|
|
Combination therapies for neoplastic disorders.
|
|
WO2009108912A1
|
|
Protein kinase modulators
|
|
WO2009046383A1
|
|
Quinolone analogs and methods related thereto
|
|
WO2009097014A2
|
|
Therapeutic kinase modulators
|
|
WO2009002838A1
|
|
Methods for treating ophthalmic disorders
|
|
CN101801190A
|
|
The method of treatment aberrant cell proliferation disorders
|
|
WO2008131134A1
|
|
Hydrazide compounds and uses thereof
|
|
WO2008064043A2
|
|
Methods for determining therapeutic efficacy of quinolone analogs
|
